Neuro-Bio is a privately owned biotech out of Oxford University with a therapeutic focus on neurodegenerative disease. The company has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE.

T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration.

This new distinct mechanism is being exploited by Neuro-Bio to develop exciting new drugs to treat Alzheimer’s disease. Neuro-Bio can also measure t14 in blood and is developing this biomarker as a companion diagnostic.